6.32  -0.1 (-1.56%)		04-07 16:00
Open: 6.29 High: 6.43 Volume: 144,201		Pre. Close: 6.42 Low: 6.115 Market Cap: 181(M)

Short term
Mid term
Targets	6-month :	8.79	1-year :	10.15
Resists	First :	7.53	Second :	8.69
Pivot price	6.65
Supports	First :	5.65	Second :	4.7
MAs	MA(5) :	6.34	MA(20) :	6.92
	MA(100) :	7.69	MA(250) :	7.89
MACD	MACD :	-0.5	Signal :	-0.5
%K %D	K(14,3) :	29.9	D(3) :	29.5
RSI	RSI(14): 38.9
52-week	High :	9.92	Low :	4.67

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ FENC ] has closed above bottom band by 37.5%. Bollinger Bands are 114.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	6.44 - 6.47	6.47 - 6.5
Low:	6.03 - 6.07	6.07 - 6.11
Close:	6.25 - 6.32	6.32 - 6.38

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Tue, 07 Apr 2026
Fennec Pharmaceuticals: University of Arizona launches PEDMARK study in AYA and adult cisplatin patients - TradingView

Tue, 07 Apr 2026
Fennec (FENC) backs new University of Arizona study on PEDMARK use in cisplatin-treated patients - Stock Titan

Tue, 07 Apr 2026
Can a hearing-loss drug help more adults on cisplatin? Arizona study starts - Stock Titan

Thu, 02 Apr 2026
[Form 4] FENNEC PHARMACEUTICALS INC. Insider Trading Activity - Stock Titan

Thu, 02 Apr 2026
Fennec (FENC) CEO gets 200,000 options and new common shares - Stock Titan

Thu, 02 Apr 2026
CMO at Fennec (NASDAQ: FENC) receives 120,000 stock options award - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	34 (M)
Shares Float	19 (M)
Held by Insiders	14.1 (%)
Held by Institutions	53.3 (%)
Shares Short	807 (K)
Shares Short P.Month	812 (K)

EPS	-0.35
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.02
Profit Margin	-22.7 %
Operating Margin	-21.9 %
Return on Assets (ttm)	-7.4 %
Return on Equity (ttm)	-69.1 %
Qtrly Rev. Growth	73.8 %
Gross Profit (p.s.)	1.19
Sales Per Share	1.3
EBITDA (p.s.)	-0.2
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-18.06
PEG Ratio	0
Price to Book value	6.13
Price to Sales	4.83
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.